Renaissance Technologies - BROOKLYN IMMUNOTHERAPEUTICS ownership

BROOKLYN IMMUNOTHERAPEUTICS's ticker is BTX and the CUSIP is 114082100. A total of 46 filers reported holding BROOKLYN IMMUNOTHERAPEUTICS in Q2 2021. The put-call ratio across all filers is 2.26 and the average weighting 0.1%.

Quarter-by-quarter ownership
Renaissance Technologies ownership history of BROOKLYN IMMUNOTHERAPEUTICS
ValueSharesWeighting
Q3 2022$360,000
-42.8%
1,459,626
+20.1%
0.00%0.0%
Q2 2022$629,000
-47.3%
1,215,800
+108.8%
0.00%0.0%
Q1 2022$1,194,000
-3.8%
582,392
+95.6%
0.00%
-50.0%
Q4 2021$1,241,000
+1577.0%
297,709
+1399.8%
0.00%
Q1 2021$74,00019,8500.00%
Other shareholders
BROOKLYN IMMUNOTHERAPEUTICS shareholders Q2 2021
NameSharesValueWeighting ↓
Cypress Point Wealth Management, LLC 471,878$8,499,0006.04%
BALDWIN BROTHERS LLC/MA 44,116$795,0000.09%
DOWLING & YAHNKE LLC 15,806$285,0000.02%
INVERNESS COUNSEL LLC /NY/ 13,307$240,0000.01%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 15,000$270,0000.01%
Cutler Group LLC / CA 4,200$75,0000.00%
MetLife Investment Management, LLC 10,805$194,5980.00%
HAP Trading, LLC 13,900$64,0000.00%
METROPOLITAN LIFE INSURANCE CO/NY 8,272$148,9790.00%
Ameritas Investment Partners, Inc. 1,867$34,0000.00%
View complete list of BROOKLYN IMMUNOTHERAPEUTICS shareholders